These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 14739041)

  • 1. Phase I study of escalating doses of oxaliplatin in combination with fixed dose gemcitabine in patients with non-small cell lung cancer.
    Bidoli P; Stani SC; Mariani L; De Candis D; Cortinovis D; Aglione S; Zilembo N; Toffolatti L; Formisano B; Bajetta E
    Lung Cancer; 2004 Feb; 43(2):203-8. PubMed ID: 14739041
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I-II and pharmacokinetic study of gemcitabine combined with oxaliplatin in patients with advanced non-small-cell lung cancer and ovarian carcinoma.
    Faivre S; Le Chevalier T; Monnerat C; Lokiec F; Novello S; Taieb J; Pautier P; Lhommé C; Ruffié P; Kayitalire L; Armand JP; Raymond E
    Ann Oncol; 2002 Sep; 13(9):1479-89. PubMed ID: 12196375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I trial of gemcitabine and carboplatin in metastatic non-small-cell lung cancer: a Groupe Français de Pneumo-Cancérologie Study.
    Thomas P; Robinet G; Ferri-Dessens RM; Léna H; Gouva S; Vernejoux JM; Kleisbauer JP
    Lung Cancer; 2002 May; 36(2):191-8. PubMed ID: 11955654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A phase I study of gemcitabine and irinotecan as second line treatment for advanced non-small cell lung cancer].
    Ryo H; Toyama K; Isobe K; Sugino K; Sano G; Yamada H; Hiroi M; Hojyo T; Kimura K
    Gan To Kagaku Ryoho; 2003 Feb; 30(2):237-42. PubMed ID: 12610872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
    Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I study of gemcitabine and carboplatin in advanced non-small cell lung carcinoma.
    Gajra A; Mehdi SA; Kirshner J; Newman N; Graziano SL
    Lung Cancer; 2001 May; 32(2):189-96. PubMed ID: 11325490
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors.
    Mavroudis D; Pappas P; Kouroussis C; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Vardakis N; Nikolaidou M; Samonis G; Marselos M; Georgoulias V
    Ann Oncol; 2003 Feb; 14(2):304-12. PubMed ID: 12562660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination phase I study of nedaplatin and gemcitabine for advanced non-small-cell lung cancer.
    Kurata T; Tamura K; Yamamoto N; Nogami T; Satoh T; Kaneda H; Nakagawa K; Fukuoka M
    Br J Cancer; 2004 Jun; 90(11):2092-6. PubMed ID: 15150564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small-cell lung cancer: a phase I study.
    Frasci G; Panza N; Comella P; Nicolella GP; Natale M; Pacilio C; Gravina A; Caputi V; Botti G; Comella G
    Ann Oncol; 1997 Oct; 8(10):1045-8. PubMed ID: 9402180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and pharmacologic study of weekly gemcitabine and paclitaxel in chemo-naïve patients with advanced non-small-cell lung cancer.
    De Pas T; de Braud F; Danesi R; Sessa C; Catania C; Curigliano G; Fogli S; del Tacca M; Zampino G; Sbanotto A; Rocca A; Cinieri S; Marrocco E; Milani A; Goldhirsch A
    Ann Oncol; 2000 Jul; 11(7):821-7. PubMed ID: 10997809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of a weekly schedule of oxaliplatin, high-dose leucovorin, and infusional fluorouracil in pretreated patients with advanced colorectal cancer.
    Rosati G; Rossi A; Tucci A; Pizza C; Manzione L
    Ann Oncol; 2001 May; 12(5):669-74. PubMed ID: 11432626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreased myelotoxicity of gemcitabine and cisplatin in advanced non-small cell lung cancer (NSCLC) with cisplatin infusion on day 15.
    Cortesi E; Ramponi S; Corona M; Moscetti L; Grifalchi F; Oliva A; Lembo A; Gasperoni S; Padovani A
    Lung Cancer; 2001; 31(2-3):271-6. PubMed ID: 11165407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of vinorelbine and gemcitabine for inoperable stage IIIB-IV non-small-cell lung cancer.
    Isokangas OP; Knuuttila A; Halme M; Mäntylä M; Lindström I; Nikkanen V; Viren M; Joensuu H; Mattson K
    Ann Oncol; 1999 Sep; 10(9):1059-63. PubMed ID: 10572603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I study with dose escalation of gemcitabine and cisplatin in combination with ifosfamide (GIP) in patients with non-small-cell lung carcinoma.
    Bourgeois H; Billiart I; Chabrun V; Chieze S; Lemerre D; Germain T; Ferrand V; Meurice JC; Daban A; Tourani JM
    Am J Clin Oncol; 2004 Feb; 27(1):89-95. PubMed ID: 14758140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy.
    Kakolyris SS; Kouroussis C; Koukourakis M; Kalbakis K; Mavroudis D; Vardakis N; Georgoulias V
    Anticancer Res; 2002; 22(3):1891-6. PubMed ID: 12168889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose-finding study of fixed dose gemcitabine and escalating doses of ifosfamide given on days 1 and 8 in patients with advanced non-small cell lung cancer.
    Baka S; Manegold C; Buchholz E; Schott-von-Römer K; Lorigan P; Nagel S; Blackhall F; Aschroft L; Thatcher N
    Lung Cancer; 2006 Aug; 53(2):165-70. PubMed ID: 16787686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine and oxaliplatin: a safe and active regimen in poor prognosis advanced non-small cell lung cancer patients.
    Franciosi V; Barbieri R; Aitini E; Vasini G; Cacciani GC; Capra R; Camisa R; Cascinu S
    Lung Cancer; 2003 Jul; 41(1):101-6. PubMed ID: 12826318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined therapy with topotecan and gemcitabine in patients with inoperable or metastatic non-small cell lung cancer.
    Dabrow MB; Francesco MR; Gilman PB; Cantor R; Rose L; Meyer TJ
    Cancer Invest; 2003; 21(4):517-25. PubMed ID: 14533441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of escalating doses of vinorelbine in combination with oxaliplatin in patients with advanced non-small-cell lung cancer.
    Monnet I; Soulié P; de Cremoux H; Saltiel-Voisin S; Bekradda M; Saltiel JC; Brain E; Dupont-André G; Cvitkovic E
    J Clin Oncol; 2001 Jan; 19(2):458-63. PubMed ID: 11208839
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A dose escalation study of docetaxel and oxaliplatin combination in patients with metastatic breast and non-small cell lung cancer.
    Kouroussis C; Agelaki S; Mavroudis D; Kakolyris S; Androulakis N; Kalbakis K; Souglakos J; Mallas K; Bozionelou V; Pallis A; Adamtziki H; Georgoulias V
    Anticancer Res; 2003; 23(1B):785-91. PubMed ID: 12680184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.